FindTrial
Sign In

Impact of Heartfulness Meditation and Yoga on Hypertension

Molecular and Cellular Assessment Using Heartfulness Meditation and Yoga as a Preventive Intervention in Hypertension - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/01/061035
Enrollment
70
Registered
2024-01-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Heartfulness Meditation and Yoga for 12 weeks.: Heartfulness meditation and yoga will be carried out in the experimental group for 12 weeks. The participants will be on their routine me

Sponsors

Dr Mansee Thakur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Grade 1 hypertensive patient having BP ranging from 140/90 to 160/99 mmHg 2. No alteration of their antihypertensive medication in the next 3 months.

Exclusion criteria

Exclusion criteria: 1. Grade 2 Hypertension 2. Severe psychiatric comorbidities (major depression, dependency disorders, or psychosis) Coronary heart disease, myocardial infarction, pulmonary embolism, or stroke in last 3 months from the day of enrolment 3. Heart failure of New York Heart Association (NYHA) stage I 4. Peripheral arterial occlusive disease of stage 1 5. Renal failure of stage >2 with glomerular filtration rate 6. Participation in any other clinical studies at the time of commencement of our trial or planned participation in such studies in the next 12 weeks 7. Practiced yoga for 30 days or more in the previous 6 months 8.Pregnancy or breastfeeding.

Design outcomes

Primary

MeasureTime frame
1. Mean score of Brief Symptom Inventory (BSI-18). 2. Monitoring of BP and ECG. 3. Corticotropin, copeptin and MDA levels. 4. Levels of pro-inflammatory markers. 5. Gene expression of NF-?B.Timepoint: 12 weeks—

Secondary

MeasureTime frame
1. A decrease in exposure to risk factors and lifestyle changes that lead to a reduction / Preventive practice for Hypertension. 2. An improvement in quality of life and a decrease in the prevalence of stress. 3. Increased awareness of current evidence and the generation of solid evidence from a randomized controlled trial of Heartfulness meditation to help health professionals integrate it into routine Hypertension secondary prevention programs.Timepoint: 12 weeks—

Countries

India

Contacts

Public ContactMs Pooja Singh

MGMSBS, MGMIHS

mansibiotech79@gmail.com09769909212

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026